Recruiting

Testing a new cancer drug for people with genetic mutations

Plain-English translation of NCT04890613 on ClinicalTrials.gov ↗ · Source last updated June 2026 · Translation generated June 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This trial is testing a new medication called (pidnarulex) for people with advanced pancreatic, ovarian, prostate, or breast cancer who have specific genetic mutations. The medication works by targeting cancer cells that have damage in their DNA repair systems, making them unable to survive. Early studies suggest this treatment has promise, and researchers want to find the best dose and confirm it is safe and effective.

People with certain genetic mutations—like BRCA1, BRCA2, or PALB2—have cancer cells that struggle to repair their DNA damage. This medication is designed to take advantage of that weakness by attacking the cancer cells in a way that healthy cells can better resist, potentially offering a new treatment option for cancers that are hard to treat with standard approaches.

Do you qualify?

You likely qualify if…

you have been diagnosed with pancreatic, ovarian, prostate, or breast cancer (or ovarian, fallopian tube, or peritoneal cancer for one part of the trial) that has grown despite previous treatment
you have a confirmed genetic mutation in one of several genes, including BRCA1, BRCA2, PALB2, or other DNA-repair-related genes, as shown by a certified genetic test
you are 18 years or older and in reasonably good overall health
you have measurable cancer visible on imaging scans taken within the past 4 weeks
your blood counts, kidney function, and liver function are in acceptable ranges based on recent lab work

You likely don't qualify if…

you have received a recent blood transfusion within 7 days of screening
your bone marrow, kidney, or liver function is severely impaired
you do not have a confirmed genetic mutation in the genes being studied
you have other serious health conditions that would make it unsafe to participate

What participation looks like

If you join this trial, you will receive the medication as an intravenous infusion (through a vein in your arm) on Day 1 and Day 8 of each 28-day cycle. Each infusion takes about an hour. You will have regular blood tests and imaging scans to check how you are responding and monitor for side effects. The study aims to confirm the safest and most effective dose, so some participants may receive a higher dose once the lower dose is proven safe.

AI-generated summary from trial data · Jun 24, 2026 · Not medical advice

Trial locations(8 sites)

United States

University of California, Los Angeles, Santa Monica, California

H. Lee Moffitt Cancer Center and Research Institute Hospital, Tampa, Florida

Dana Farber Cancer Institute, Boston, Massachusetts

Memorial Sloan-Kettering Cancer Center, New York, New York

Ohio State University-James Cancer Hospital and Solove Research Institute, Columbus, Ohio